Objective: To evaluate microRNA let7i in ischemic stroke and its regulation of leukocytes.
Ischemic stroke remains a leading cause of disability. Although early reperfusion therapy can improve outcomes, it is available to a minority of stroke patients. Specific therapies are needed to reduce brain injury and improve outcomes after stroke. The immune system responds rapidly following cerebral ischemia. A range of damage-associated molecular patterns, cytokines, and chemokines are released to activate circulating leukocytes, vasculature, and brain cells. 1, 2 This inflammatory response has an important role in acute ischemic stroke and can contribute to the final extent of brain damage. Improved understanding of the immune response in stroke and its regulation may afford novel opportunities to optimize recovery in ischemic stroke.
microRNAs are important epigenetic regulators of the immune system. They fine tune gene expression with known roles in regulating nuclear factor kB signaling, toll-like receptor signaling, and cytokine expression. We previously identified let7i to be decreased in leukocytes of patients with acute ischemic stroke. 3 In this study, we evaluate let7i regulation of the peripheral immune response in patients with acute ischemic stroke.
Let7i is part of the let7 microRNA family. It is a broadly conserved microRNA that has important roles in cell regulation, differentiation, and signaling. In stroke, members of the let7 family have been shown to modulate endothelial cells as well as brain insulin-like growth factor-1. 4, 5 However, let7i regulation of leukocytes following stroke remains unknown. Further understanding of let7i microRNA and its target gene regulation in stroke is required to understand its role in brain injury and its regulation of the immune system post stroke.
METHODS Standard protocol approvals, registrations, and patient consents. Participants were recruited from the University of California Davis from December 2012 to January 2015. The institutional review board at the University of California Davis approved the study protocol, and all participants provided written informed consent.
Study population. In total, 106 patients with acute ischemic stroke and 106 controls with vascular risk factors were studied. The diagnosis of ischemic stroke was made based on clinical presentation consistent with stroke and evidence of diffusion restriction on brain MRI (restricted diffusion on diffusionweighted MRI). Two board-certified neurologists reviewed each patient independently, and agreement was required for diagnosis. Patients excluded from the study had infection (active or in the preceding 14 days of stroke), treatment with immunosuppression, leukemia, or lymphoma. Controls were patients similar in age, sex, and race/ethnicity with vascular risk factors but with no history of cardiovascular disease (stroke, peripheral vascular disease, or coronary ischemia). microRNA isolation. microRNA was isolated from whole blood acquired in PAXgene tubes (BD/PreAnalytiX, Franklin Lakes, NJ). PAXgene tubes contain an RNA stabilizing reagent that acts at time of blood draw to prevent RNA degradation. RNA in whole blood is derived mainly from peripheral blood cells (monocytes, neutrophils, T cells, B cells, and megakaryocytes). Blood samples were acquired in the first 72 hours from the onset of stroke and placed in storage at 280 8 C. RNA was isolated using a PAXgene microRNA kit (PreAnalytiX). Concentration of RNA was ascertained by NanoDrop (ThermoFisher, Waltham, MA) and quality by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). All samples had a 28S/18S ribosomal RNA ratio $1.8, RNA integrity number $8, A 260 /A 230 ratio $1.8, and an A 260 /A 280 ratio $1.8.
Let7i measurement. A TaqMan microRNA assay was used to evaluate hsa-let-7i-5p (referred to as let7i) expression (TaqMan microRNA assay ID 002221) (mature microRNA sequence: UGAGGUAGUAGUUUGUGCUGUU) (Applied Biosystems, Foster City, CA). Total RNA (25 ng for each participant) was reverse transcribed into complementary DNA (cDNA) using a TaqMan microRNA RT Kit and RT Primers. cDNA was amplified by RT-PreAmp Primer and TaqMan PreAmp Master Mix (ThermoFisher). The PreAmp product was combined with TaqMan microRNA assay ID 002221 and TaqMan Universal PCR Master Mix and processed using a 7900HT Fast Real-Time PCR System (ThermoFisher). RQ manager was used to ascertain cycle thresholds with U75 serving as the endogenous control.
The expression of let7i in ischemic stroke was assessed in relation to controls. To identify factors that differed between patients with ischemic stroke and controls, univariate analysis was performed using 2-tailed t test, x 2 , and Mann-Whitney test as appropriate (Stata 11.0; StataCorp, College Station, TX). Multivariate analysis using analysis of variance was then performed to evaluate the expression of let7i in ischemic stroke and controls including factors identified on univariate analysis with a p , 0.2 (Partek Genomics Suite 6.6; Partek Inc., St. Louis, MO).
Messenger RNA targets of let7i. To identify the messenger RNA (mRNA) targets that may be regulated by let7i, we performed an analysis comparing the expression level of let7i to mRNA in circulating leukocytes. mRNA was measured using whole-genome Affymetrix Human Transcriptome Array (HTA) 2.0 microarray (Affymetrix, Santa Clara, CA). mRNA was isolated from whole blood collected and stabilized in PAXgene tubes (PreAnalytiX/BD). Total RNA was isolated using the PAXgene Blood mRNA isolation kits with quantity assessed by Nanodrop and quality by an Agilent 2100 Bioanalyzer. For each sample, 75 ng of total RNA was prepared using the GeneChip WT PLUS Reagent Kit following manufacturer's protocols. Labeled cDNA from each sample was hybridized to an HTA 2.0 microarray and scanned using a GeneChip Scanner 3000 7G (Affymetrix).
HTA 2.0 microarray data were normalized using Robust Multiarray Average (RMA), log 2 -transformed, and summarized to the gene transcript level (Partek Genomics Suite 6.6). Gene transcripts were filtered to targets of let7i based on databases of microRNA gene targets (TargetScan 7.0 homo sapiens, Ingenuity Pathway Analysis, Tarbase v7.0, miRecords). Gene transcripts were deemed targets if previous regulation by let7i had been reported or the weighted context11 score was less than 20.2 indicating increased likelihood of being a target. 6 The expression of let7i was compared to the expression of predicted gene targets using Pearson correlation. Gene targets that inversely correlated with let7i expression with an r # 20.2 and p , 0.05 were considered regulated targets in stroke. This is based on the principle that a microRNA causes mRNA degradation and translational repression. Functional analysis of the identified targets was performed in Ingenuity Pathway Analysis. Overrepresented pathways predicted to be regulated by let7i in ischemic stroke were identified (table 1) .
Enzyme-linked immunosorbent assay. Plasma protein expression was determined using ELISA for human MMP9 according to the manufacturer's protocol (R&D Systems, Minneapolis, MN). Plasma from patients was acquired in an EDTA tube. Abbreviations: NF-kB 5 nuclear factor kB; TFNb 5 transforming growth factor b.
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Samples were centrifuged at 1,000g for 10 minutes with plasma removed and stored frozen at 280 8 C within 1 hour of collection. 
were not found to correlate with let7i including age, sex, systolic blood pressure, and admission serum glucose.
To identify gene targets regulated by let7i in patients with acute ischemic stroke, the expression of genes in circulating leukocytes was assessed. A decrease in let7i correlated with an increase in several of its predicted gene targets (table e- To determine functional pathways regulated by let7i in circulating leukocytes of patients with ischemic stroke, gene targets that inversely correlated with let7i expression were evaluated for common overrepresented pathways. Functional pathways identified included leukocyte activation, recruitment, and proliferation (table 1) . Canonical pathways identified included CD86 signaling in T helper cells, HMGB1 signaling, and CXCL8 signaling.
To test the posttranscriptional regulation of let7i on CD86, CXCL8, and HMGB1, a luciferase reporter assay was performed. The 39UTR for CD86, CXCL8, or HMGB1 fused to a luciferase reporter gene was cotransfected with let7i microRNA or scrambled microRNA, or no microRNA and assayed 24 hours after transfection. No significant change was observed when an empty reporter vector was cotransfected with let7i or scrambled microRNA. No significant change occurred when let7i mimic or scrambled microRNA DISCUSSION Let7i microRNA decreased in circulating leukocytes of patients with acute ischemic stroke. A primary function of microRNA is to bind mRNA to trigger degradation and translational repression. To evaluate this regulatory role of let7i microRNA in ischemic stroke, let7i gene targets expressed in leukocytes were analyzed. Let7i gene targets identified were involved in leukocyte proliferation and activation including HMGB1, CD86, and CXCL8. Let7i also decreased as infarct severity and plasma MMP9 increased. These data suggest that let7i regulates the peripheral immune system in patients with acute ischemic stroke, and this regulation may relate to severity of ischemic brain injury. The regulation of the immune response by let7i in ischemic stroke is supported by prior studies demonstrating that let7i regulates immune cell response to infection. [7] [8] [9] In stroke, let7i regulated leukocytes through target genes involved in proliferation, activation, and recruitment. This raises the question as to whether let7i could be used as a stroke therapy to modulate the leukocyte response. It could potentially modulate inflammatory response to ischemic brain and blood-brain barrier. microRNA has shown promise as a treatment for a number of diseases including cancer, atherosclerosis, heart failure, hepatitis C, and spinal and bulbar muscular atrophy. [10] [11] [12] [13] [14] [15] microRNAs have several properties that make them attractive as a therapeutic agent. Their nucleotide sequence permits specific gene regulation, while their small size facilitates delivery. microRNAs generally target several genes in the same pathway or network permitting modulation of a disease state at multiple levels. While potentially useful in complex disease, this property may also produce off-target effects whereby a microRNA regulates expression of genes not involved in the disease process. With further study, improved targeting and delivery of microRNA may reduce these off-target effects.
CD86 promotes inflammation post stroke and may contribute to brain injury. Our data indicate that let7i is a regulator of CD86-related inflammation in stroke. CD86 increased as let7i decreased (r 5 20.43, p 5 0.002) as did CD28, the receptor for CD86 (r 5 20.36, p 5 0007). CD86 is expressed by activated monocytes and B cells to promote inflammation and T cell activation. In ischemic stroke, an increase in CD86 monocytes (M1 proinflammatory Figure 1 Expression of let7i microRNA in ischemic stroke (A) Relative expression of let7i in patients with acute ischemic stroke (n 5 106) compared to vascular risk controls (n 5 106). Let7i decreased in leukocytes of patients with acute ischemic stroke compared to controls (fold change 5 21.70, p 5 0.00001). A decrease in level of let7i correlated modestly with (B) an increase in NIHSS score at admission, (C) an increase in infarct volume (log 10 mm 3 ), and (D) an increase in plasma MMP9 (log 10 pg/mL) in patients with acute ischemic stroke. CT 5 cycle threshold; NIHSS 5 NIH Stroke Scale; RQ 5 relative quantification.
phenotype) is associated with worse functional outcome, 16, 17 and CD86 monocytes can promote neurotoxicity that worsens neurologic injury.
18 CD86 stimulation of CD28 results in the production of inflammatory cytokines (interleukin [IL]-6, tumor necrosis factor a [TNF-a], CCL2, TNFSF11, transforming growth factor b) as well as promotes leukocyte activation, chemotaxis, and recruitment. 19 Blocking CD28 post stroke reduces infarct size, improves behavioral outcomes, and reduces the inflammatory response. 20, 21 Our study suggests that a decrease in let7i may promote this detrimental immune response post stroke by increasing expression of CD86.
Let7i may also regulate CXCL8 (IL-8, neutrophil chemotactic factor) in stroke. CXCL8 is a chemokine produced by activated macrophages and endothelial cells. It binds CXCR1 and CXCR2 to promote neutrophil chemotaxis, activation, degranulation, and release of MMP9.
22 CXCL8 can promote tissue injury 23 and is associated with infarct severity in humans 24 and rodents. 25, 26 Thus, regulation of CXCL8 may be essential to limit injury to ischemic brain. We found the decrease of let7i in stroke to be associated with an increase in CXCL8 as well as an increase in stroke severity. This suggests let7i may permit an increase in CXCL8, promoting neutrophil activation in relation to stroke severity.
HMGB1 expressed in circulating leukocytes post stroke was found to be regulated by let7i. HMGB1 is released following tissue injury to mediate innate immunity and repair. It promotes leukocyte proliferation and chemotaxis to sites of injury. It is produced by most cells including brain and leukocytes. Previous studies show that HMGB1 increases in patients with ischemic stroke and correlates with the number of circulating leukocytes, 27 stroke severity (NIHSS score, infarct size), and inflammatory markers (TNF-a, IL-1, IL-6, MMP9). [28] [29] [30] [31] These findings are consistent with our study whereby a decrease in let7i was associated with a rise in HMGB1 as well as an increase in inflammatory response, MMP9, and infarct size.
Plasma levels of MMP9 increased with a decrease in let7i. The explanation for this relationship requires further study, as we did not find let7i to correlate with MMP9 mRNA or to regulate MMP9 via its 39UTR. One explanation might be that a decrease in let7i permits a proliferation of neutrophils, a major source of plasma MMP9 post stroke. 1 However, let7i remained correlated with MMP9 when neutrophil count was adjusted for. Alternatively, MMP9 may have increased because of let7i regulation of genes that affect the production and release of MMP9. 32 The decrease in let7i did correlate with an increase in several genes that affect MMP9, including CHUK, PIN1, CRK, TNFSF10, IGFBP7. Potentially MMP9 plasma levels are indirectly affected by let7i's effect on these targets.
In patients with more severe strokes (increased infarct size, increased NIHSS score), let7i levels were lower. While the significance of this finding requires further study, it may indicate that let7i regulates the immune response in relation to severity of stroke. A relationship between brain and leukocyte gene expression Correlation of let7i with gene targets CD86, CXCL8, HMGB1 in circulating leukocytes of patients with acute ischemic stroke
The y-axis is the relative expression of messenger RNA transcript based on normalized intensity values from the Human Transcriptome Array 2.0 Affymetrix microarray. The x-axis is the relative expression of let7i based on delta Ct values from TaqMan reverse transcription PCR. As let7i decreased, levels of CD86, CXCL8, and HMGB1 increased suggesting a regulatory effect of let7i for these targets in ischemic stroke. The binding site of let7i in the 39UTR of CD86, CXCL8, and HMGB1 is shown below each scatterplot. 39UTR 5 39 untranslated region.
and microRNA regulation has been observed in experimental stroke. 33, 34 In stroke patients, infarct size has been associated with inflammatory response, with levels of TNF-a, 35 IL-6, 36,37 ICAM1, 35 MMP2, and MMP9 35, 38 correlating with infarct volume. Let7i may regulate this inflammatory response post stroke through its effect on CD86, CXCL8, and HMGB1. In addition, let7i may regulate leukocyte proliferation through its effect on cell-cycle genes (E2F6, RB1, YWHAE, AURKA, and PIN1) (table 1) .
This study improves our understanding of microRNA regulation of leukocyte response in human ischemic stroke. Strengths include analysis of a large cohort of patients with rapidly stabilized RNA, wholegenome evaluation of let7i gene targets, and validation of let7i targets by in vitro analysis. Further studies are needed to evaluate the regulatory role of let7i at the individual immune cell level. Functional analysis was based on gene targets that inversely correlated with let7i and predicted to be likely targets of let7i. Selected mRNA targets were analyzed by in vitro analysis but additional target analyses are needed to comprehensively understand let7i regulation of targets and pathways important in ischemic stroke. The representation of larger strokes was small relative to the mild-moderate group, thus further evaluation of let7i in severe strokes is needed.
Let7i microRNA is shown to decrease in patients with acute ischemic stroke and to modulate the peripheral immune system. Mechanisms by which let7i regulates inflammatory response in stroke include targeting CD86, CXCL8, and HMGB1. 
